Pfizer Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PFE research report →
Companywww.pfizer.com
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- CEO
- Albert Bourla
- IPO
- 1972
- Employees
- 81,000
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $146.96B
- P/E
- 19.59
- P/S
- 2.32
- P/B
- 1.63
- EV/EBITDA
- 12.38
- Div Yield
- 6.67%
Profitability
- Gross Margin
- 69.35%
- Op Margin
- 23.45%
- Net Margin
- 11.83%
- ROE
- 8.37%
- ROIC
- 7.97%
Growth & Income
- Revenue
- $62.58B · -1.65%
- Net Income
- $7.77B · -3.12%
- EPS
- $1.36 · -4.23%
- Op Income
- $15.44B
- FCF YoY
- -7.72%
Performance & Tape
- 52W High
- $28.75
- 52W Low
- $22.81
- 50D MA
- $26.88
- 200D MA
- $25.78
- Beta
- 0.30
- Avg Volume
- 37.86M
Get TickerSpark's AI analysis on PFE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | BOURLA ALBERT | other | 24 |
| Apr 30, 26 | BOURLA ALBERT | other | 22 |
| Apr 23, 26 | Gottlieb Scott | other | 7,686.539 |
| Apr 23, 26 | NORA JOHNSON SUZANNE M | other | 7,686.539 |
| Apr 23, 26 | LITTMAN DAN R. | other | 7,686.539 |
| Apr 23, 26 | BLAYLOCK RONALD E | other | 7,686.539 |
| Apr 23, 26 | Buckley Mortimer J | other | 7,686.539 |
| Apr 23, 26 | Desmond-Hellmann Susan | other | 7,686.539 |
| Apr 23, 26 | Echevarria Joseph | other | 7,686.539 |
| Apr 23, 26 | NARAYEN SHANTANU | other | 7,686.539 |
Our PFE Coverage
We haven't published any research on PFE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PFE Report →